|
시장보고서
상품코드
1789370
세계의 응고인자 결핍증 시장 : 질환 유형별, 치료 유형별, 제형별, 투여 경로별, 연령층별, 최종사용자별, 지역별Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography |
||||||
응고인자 결핍증 시장은 2025년에는 50억 1,000만 달러, 2032년에는 89억 달러에 이르고, 2025-2032년 연평균 복합 성장률(CAGR)은 8.2%를 나타낼 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 50억 1,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 CAGR(2025-2032년) | 8.20% | 예측 금액(2032년) | 89억 달러 |
세계 응고인자 결핍증 시장은 희귀하지만 생명을 위협하는 유전성 출혈성 질환으로 정상적인 지혈에 필수적인 특정 응고인자의 결손 또는 기능 장애를 특징으로 하는 광범위한 혈액학 치료제 중 중요한 부문입니다. 응고인자 결핍증에는 혈우병 A(제8인자 결핍증), 혈우병 B(제9인자 결핍증), 그리고 제 I, II, V, VII, X, XI, XIII 인자를 포함한 희귀 결핍증이 있으며, 전 세계적으로 약 40만 명이 앓고 있습니다.
이러한 질환은 출혈 에피소드의 장기화, 자연 출혈, 수술의 위험 증가로 나타나며, 인자 보충 요법, 예방적 치료, 새로운 유전자 치료를 통한 평생 관리가 필요합니다. 동 시장은 기술의 발전과 응고 캐스케이드 메커니즘에 대한 이해의 향상으로 혈장 유래 농축제제에서 재조합 인자 제제 및 반감기 연장 제제로 크게 진화하고 있습니다. 의료진의 인식 제고, 진단 능력 향상, 환자 등록 개선, 신흥국 시장에서의 전문 의료 서비스 접근성 확대 등이 시장 개척에 기여하고 있습니다. 비인자 요법, 피하주사, 유전자 편집 기술 등 혁신적인 접근법으로 치료 환경은 계속 변화하고 있으며, 이러한 만성 질환에 따른 경제적 부담을 해소하고 환자의 편의성 향상과 삶의 질 개선을 실현하고 있습니다.
시장 역학
세계 응고인자 결핍증 시장은 선진국과 신흥국 시장에서 상호 연관된 여러 요인에 의해 강력한 성장 동력을 보이고 있습니다. 주요 시장 성장 촉진요인으로는 진단 기술 향상과 신생아 선별검사 프로그램 확대에 따른 유전성 출혈성 질환의 유병률 증가를 들 수 있으며, 이는 조기 발견 및 치료 시작을 촉진하고 있습니다. 바이오테크놀러지의 기술적 발전은 치료 패러다임에 혁명을 가져왔고, 반감기가 연장된 유전자 재조합 인자의 개발은 주사 횟수를 줄이고 환자의 순응도를 높였으며, 에미시주맙과 같은 새로운 비인자 요법은 억제제 환자에게 대체 치료 옵션을 제공합니다. 신흥국을 중심으로 한 의료비 지출 증가와 인식 개선 캠페인 및 환자 지원 활동의 활성화가 맞물려 시장 접근성이 확대되고, 첨단 치료제에 대한 수요가 증가하고 있습니다. 희귀질환 연구 및 희귀질환 치료제 개발을 지원하는 정부 이니셔티브는 규제 혜택과 신속한 승인 경로를 통해 시장 성장을 더욱 촉진할 수 있습니다. 그러나 농축인자 제제 및 고급 치료제에 소요되는 막대한 비용이 시장의 큰 억제요인으로 작용하고 있으며, 자원이 부족한 환경에서는 접근성이 제한되어 의료 시스템에 큰 경제적 부담을 주고 있습니다. 중증 혈우병 A 환자의 약 25-30%에서 중화항체(억제제)가 개발되어 치료전략이 복잡해지고 치료비용이 증가하고 있습니다. 신흥국 시장의 낮은 의료 서비스 제공업체 인지도, 제품 유통을 위한 콜드체인 인프라 미비, 서로 다른 시장 간의 복잡한 규제는 또 다른 도전이 되고 있습니다. 혈장 유래 제품공급망 혼란과 혈장 부족은 시장의 불안정성을 야기하고 있습니다. 그럼에도 불구하고, 잠재적인 기능적 치료법과 장기적으로 비용 대비 효과가 기대되는 유전자 치료제의 개발이 확대되면서 큰 비즈니스 기회가 창출되고 있습니다. 개인화된 의료 접근 방식에 대한 관심 증가, 원격 환자 모니터링을 위한 원격 의료 통합, 아시아태평양 및 중남미 시장에서의 헬스케어 인프라 투자 증가는 시장 확대의 큰 잠재력을 보여주고 있습니다.
본 보고서의 주요 특징
- 세계의 응고인자 결핍증 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 응고인자 결핍증 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기준으로 정리했습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 응고인자 결핍증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 응고인자 결핍증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 응고인자 결핍증 시장, 질환 유형별(2020-2032년)
- 혈우병 A(제VIII인자 결핍증)
- 혈우병 B(제IX인자 결핍증)
- 혈우병 C(제XI인자 결핍증)
- 폰 빌레브란트병
- 희귀인자 결핍
제5장 세계의 응고인자 결핍증 시장, 치료 유형별(2020-2032년)
- 보충 요법
- 비치환 요법
- 유전자 치료
- 기타(호르몬 요법)
제6장 세계의 응고인자 결핍증 시장 : 제형별(2020-2032년)
- 재구성용 동결건조 분말
- 주사/점적 용액체 용액
- 경구 제제
- 비강 스프레이
- 기타 바이러스 벡터 현탁액
제7장 세계의 응고인자 결핍증 시장 : 투여 경로별(2020-2032년)
- 정맥내
- 피하
- 비강내
- 경구
제8장 세계의 응고인자 결핍증 시장 : 연령층별(2020-2032년)
- 소아
- 성인
제9장 세계의 응고인자 결핍증 시장 : 최종사용자별(2020-2032년)
- 병원
- 전문 약국
- 혈우병 치료 센터
- 재택치료
- 전문 클리닉
- 외래수술센터(ASC)
- 기타(학술연구기관 등)
제10장 세계의 응고인자 결핍증 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제11장 경쟁 구도
- Baxter International Inc.
- CSL Behring
- Grifols S.A.
- Takeda Pharmaceutical Company
- Novo Nordisk A/S
- Pfizer Inc.
- Bayer AG
- Sobi(Swedish Orphan Biovitrum)
- Biogen Inc.
- Octapharma AG
- Sanofi S.A.
- Amgen Inc.
- Genentech, Inc.
- UCB S.A.
제12장 애널리스트의 제안
- 'Wheel of Fortune'
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제13장 참고 문헌과 조사 방법
- 참고 문헌
- 분석 방법
- Coherent Market Insights에 대해
Coagulation Factor Deficiency Market is estimated to be valued at USD 5.01 Bn in 2025 and is expected to reach USD 8.90 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 5.01 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.20% | 2032 Value Projection: | USD 8.90 Bn |
The global coagulation factor deficiency market represents a critical segment within the broader hematology therapeutics landscape, addressing rare but life-threatening inherited bleeding disorders characterized by the absence or dysfunction of specific clotting factors essential for normal hemostasis. Coagulation factor deficiencies encompass a spectrum of conditions including hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and rarer deficiencies involving factors I, II, V, VII, X, XI, and XIII, collectively affecting approximately 400,000 individuals worldwide.
These disorders manifest through prolonged bleeding episodes, spontaneous hemorrhages, and increased surgical risks, necessitating lifelong management through factor replacement therapies, prophylactic treatments, and emerging gene therapies. The market has witnessed substantial evolution from plasma-derived concentrates to recombinant factors and extended half-life products, driven by technological advancements and improved understanding of coagulation cascade mechanisms. Rising awareness among healthcare professionals, enhanced diagnostic capabilities, improved patient registries, and expanding access to specialized care in developing regions contribute to market growth. The therapeutic landscape continues to transform with innovative approaches including non-factor therapies, subcutaneous formulations, and gene editing technologies, offering enhanced convenience and improved quality of life for patients while addressing the substantial economic burden associated with these chronic conditions.
Market Dynamics
The global coagulation factor deficiency market demonstrates robust growth dynamics driven by multiple interconnected factors that shape its trajectory across developed and emerging markets. Primary market drivers include the increasing prevalence of inherited bleeding disorders due to improved diagnostic techniques and expanded newborn screening programs, which enhance early detection and treatment initiation. Technological advancements in biotechnology have revolutionized treatment paradigms, with the development of extended half-life recombinant factors reducing injection frequency and improving patient compliance, while novel non-factor therapies like emicizumab provide alternative treatment options for patients with inhibitors. Rising healthcare expenditure, particularly in emerging economies, coupled with growing awareness campaigns and patient advocacy initiatives, expands market accessibility and drives demand for advanced therapeutics. Government initiatives supporting rare disease research and orphan drug development, including regulatory incentives and expedited approval pathways, further stimulate market growth. However, significant market restraints persist, primarily centered around the prohibitive cost of factor concentrates and advanced therapies, which limit accessibility in resource-constrained settings and create substantial financial burden on healthcare systems. The development of neutralizing antibodies (inhibitors) in approximately 25-30% of severe hemophilia A patients complicates treatment strategies and increases therapeutic costs. Limited awareness among healthcare providers in developing regions, inadequate cold chain infrastructure for product distribution, and regulatory complexities across different markets pose additional challenges. Supply chain disruptions and plasma shortages for plasma-derived products create market volatility. Nevertheless, substantial opportunities emerge from expanding gene therapy developments, which promise potential functional cures and long-term cost-effectiveness. Growing focus on personalized medicine approaches, telemedicine integration for remote patient monitoring, and increasing healthcare infrastructure investments in Asia Pacific and Latin American markets present significant growth potential for market expansion.
Key Features of the Study
- This report provides an in-depth analysis of the global coagulation factor deficiency market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global coagulation factor deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Baxter International Inc., CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Novo Nordisk A/S, Pfizer Inc., Bayer AG, Sobi (Swedish Orphan Biovitrum), Biogen Inc., Octapharma AG, Sanofi S.A., Amgen Inc., Genentech, Inc., and UCB S.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global coagulation factor deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global coagulation factor deficiency factor.
Market Segmentation
- Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
- Hemophilia A (Factor VIII Deficiency)
- Hemophilia B (Factor IX Deficiency)
- Hemophilia C (Factor XI Deficiency)
- Von Willebrand Disease
- Type 1-Mild deficiency of von Willebrand factor (VWF)
- Type 2-Abnormal function of VWF
- Rare Factor Deficiencies
- Factor I (Fibrinogen) Deficiency
- Factor II (Prothrombin) Deficiency
- Factor V Deficiency
- Factor VII Deficiency
- Factor X Deficiency
- Factor XIII Deficiency
- Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
- Replacement Therapy
- Plasma-derived Coagulation Factors
- Recombinant Coagulation Factors
- Non-replacement Therapy
- Desmopressin (DDAVP)
- Antifibrinolytics
- Anticoagulants
- Gene Therapy
- Adeno-Associated Virus (AAV) Gene Therapy
- Lentivirus Gene Therapy
- Others (Hormonal Therapy)
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Lyophilized Powder for Reconstitution
- Liquid Solution for Injection/Infusion
- Oral Formulations
- Nasal Spray
- Other Viral Vector Suspension
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
- Intranasal
- Oral
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Pharmacies
- Hemophilia Treatment Centers
- Homecare Settings
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others (Academic & Research Institutions.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Baxter International Inc.
- CSL Behring
- Grifols S.A.
- Takeda Pharmaceutical Company
- Novo Nordisk A/S
- Pfizer Inc.
- Bayer AG
- Sobi (Swedish Orphan Biovitrum)
- Biogen Inc.
- Octapharma AG
- Sanofi S.A.
- Amgen Inc.
- Genentech, Inc.
- UCB S.A.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Coagulation Factor Deficiency Market, By Disorder Type
- Global Coagulation Factor Deficiency Market, By Treatment Type
- Global Coagulation Factor Deficiency Market, By Dosage Form
- Global Coagulation Factor Deficiency Market, By Route of Administration
- Global Coagulation Factor Deficiency Market, By Age Group
- Global Coagulation Factor Deficiency Market, By End User
- Global Coagulation Factor Deficiency Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hemophilia A (Factor VIII Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hemophilia B (Factor IX Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hemophilia C (Factor XI Deficiency)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Von Willebrand Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Type 1-Mild deficiency of von Willebrand factor (VWF)
- Type 2-Abnormal function of VWF
- Rare Factor Deficiencies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Factor I (Fibrinogen) Deficiency
- Factor II (Prothrombin) Deficiency
- Factor V Deficiency
- Factor VII Deficiency
- Factor X Deficiency
- Factor XIII Deficiency
5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Plasma-derived Coagulation Factors
- Recombinant Coagulation Factors
- Non-replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Desmopressin (DDAVP)
- Antifibrinolytics
- Anticoagulants
- Desmopressin (DDAVP)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adeno-Associated Virus (AAV) Gene Therapy
- Lentivirus Gene Therapy
- Others (Hormonal Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Lyophilized Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liquid Solution for Injection/Infusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral Formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Viral Vector Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hemophilia Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Academic & Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grifols S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sobi (Swedish Orphan Biovitrum)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
